| Literature DB >> 35602005 |
Jessica Camacho1, Aline de Conti2, Igor P Pogribny2, Robert L Sprando1, Piper Reid Hunt1.
Abstract
Exposures to mercury and arsenic are known to pose significant threats to human health. Effects specific to organic vs. inorganic forms of these toxic elements are less understood however, especially for organic dimethylarsinic acid (DMA), which has recently been detected in pups of rodent dams orally exposed to inorganic sodium (meta)arsenite (NaAsO2). Caenorhabditis elegans is a small animal alternative toxicity model. To fill data gaps on the effects of DMA relative to NaAsO2, C. elegans were exposed to these two compounds alongside more thoroughly researched inorganic mercury chloride (HgCl2) and organic methylmercury chloride (meHgCl). For timing of developmental milestone acquisition in C. elegans, meHgCl was 2 to 4-fold more toxic than HgCl2, and NaAsO2 was 20-fold more toxic than DMA, ranking the four compounds meHgCl > HgCl2 > NaAsO2 ≫ DMA for developmental toxicity. Methylmercury induced significant decreases in population locomotor activity levels in developing C. elegans. DMA was also associated with developmental hypoactivity, but at >100-fold higher concentrations than meHgCl. Transcriptional alterations in native genes were observed in wild type C. elegans adults exposed to concentrations equitoxic for developmental delay in juveniles. Both forms of arsenic induced genes involved in immune defense and oxidative stress response, while the two mercury species induced proportionally more genes involved in transcriptional regulation. A transgenic bioreporter for activation of conserved proteosome specific unfolded protein response was strongly activated by NaAsO2, but not DMA at tested concentrations. HgCl2 and meHgCl had opposite effects on a bioreporter for unfolded protein response in the endoplasmic reticulum. Presented experiments indicating low toxicity for DMA in C. elegans are consistent with human epidemiologic data correlating higher arsenic methylation capacity with resistance to arsenic toxicity. This work contributes to the understanding of the accuracy and fit-for-use categories for C. elegans toxicity screening and its usefulness to prioritize compounds of concern for further testing.Entities:
Keywords: Alternative Toxicity Model; Arsenic; DEGs, Differentially Expressed Genes; DMA, dimethylarsinic acid; ER, endoplasmic reticulum; EXT, extinction (a measure of optical density); GO, gene ontology; HgCl2, mercury(ii) chloride; Inorganic; L1, first larval stage C. elegans; LD50, the median lethal dose per kilogram of body weight; LOEL, lowest observed effect level; Mercury; NOEL, no observed effect level; NaAsO2, sodium (meta)arsenite; Organic; OxStrR, Oxidative Stress Response; Predictive Toxicology; TOF, time of flight (a measure of size); UPR, Unfolded Protein Response; iAs, inorganic arsenic; meHgCl, methylmercury chloride
Year: 2022 PMID: 35602005 PMCID: PMC9118485 DOI: 10.1016/j.crtox.2022.100071
Source DB: PubMed Journal: Curr Res Toxicol ISSN: 2666-027X
Chemicals Selected for Testing.
| Compound * | Abbreviation | CAS RN | LD50 | Oral RfD | TWI |
|---|---|---|---|---|---|
| sodium (meta)arsenite | NaAsO2 | 7784–46-5 | 41 mg/kg (rat, oral) | 0.3 µg/kg-day ( | withdrawn # |
| dimethylarsinic acid (DMAV) | DMA | 75–60-5 | 700 mg/kg (rat, oral) | not established | not established |
| mercury chloride | HgCl2 | 7487–94-7 | 1 mg/kg (rat, oral) | 0.3 µg/kg-day ( | 4 µg Hg/kg-week ( |
| methylmercury chloride | meHgCl | 115–09-3 | 30 mg/kg (rat, oral) | 0.1 µg/kg-day ( | 1.3 µg Hg/kg-week ( |
CAS RN: The Chemical Abstracts Service (CAS) Registration Number (RN) is a unique numerical identifier designating a specific substance.
LD50: the median lethal dose per kilogram of body weight.
RfD: Reference Dose for chronic oral exposure, an estimate of a daily exposure that is likely to be without.
an appreciable risk of deleterious effects during a lifetime.
TWI: tolerable weekly intake, the amount per kilogram of body weight that can be ingested per week without risk of adverse health effects.
# Provisional TWI of 15 µg As/kg was withdrawn in 2009 as too high for safety (Naess et al., 2020).
* Compounds and CAS RNs listed are those purchased and used in this study. Reference values (LD50, RfD, and TWI) may be for slightly different compounds, for example the available oral RfD is for methylmercury, CAS RN 22967–92-6.
Fig. 1Developmental toxicity of inorganic vs. organic arsenic and mercury. (A) A representative example of the readout from a single worm Development and Activity Test (wDAT) for methylmercury chloride is shown. The y-axis indicates population locomotor activity levels as measured by mean infrared beam interruption values per well from a single experiment, graphed over half hour time increments on the x-axis. L1 through L4 indicates the four larval stages of C. elegans development. There are two separate sets of water controls (L and R), represented by blue and light blue lines for the left and right plates run simultaneously. The horizontal gray arrow from the y-axis indicates the control peak height of the 3rd larval stage (L3). The corresponding times for the two controls to reach the peak height for L3 are 35.5 and 36 h in this experiment. The variability for L3 peak height and timing between controls in separate plates run side-by-side was used as a measure of experimental variability and is shown in 1B-E as ‘0 L-R’. (B-E) Bars and error bars represent the means and standard deviations from four independent wDAT experiments, with the exception of those for 5.0 µg/mL HgCl2 for which there were data from only two of four experiments. (B&D) The delay in the time to reach L3 relative to controls is plotted. (C&E) L3 locomotor activity peak level relative to controls. Not assessed (n/a). T-test p-values *<0.05, ** <0.005. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2Microarray analysis of gene expression with inorganic vs. organic arsenic and mercury. Whole-genome microarray transcriptomic analysis of C. elegans exposed to 10 µg/ml NaAsO2, 200 µg/ml DMA, 0.5 µg/ml meHgCl, or 2.0 µg/ml HgCl2. A) Heat maps illustrating differences in global gene expression profiles between control and exposed adult C. elegans. B) Venn diagram illustrating the number of differentially expressed genes and their analysis in C. elegans exposed to NaAsO2 or DMA. C) Venn diagram illustrating the number of differentially express genes and their analysis in C. elegans exposed to meHgCl or HgCl2.
Fig. 3Gene Ontology (GO) terms, and genes also affected by other chemicals. WormBase’s GO terms and descriptions relating to specific functions were used to assign into categories all differentially expressed genes (DEGs) for which there was expression, function, and/or homology information in WormBase. (A-B) The number of DEGs varied among conditions, therefore bars represent the fraction of all DEGs that were in each category. Many DEGs fell into multiple categories and were therefore counted more than once. Note that the fraction of DEGs with the GO term “integral component of membrane” (Membrane Bound) are shown with a different scale. (C) The fraction of DEGs (y-axis) also altered by exposure to listed drugs (x-axis) is graphed. WormBase’s expression cluster summary only indicates that a gene’s expression is affected by a chemical, but not in which direction, therefore the fraction of DEGs also affected by various chemicals is presented for up- and downregulated DEGs together. Abbreviations: Upregulated (Up), Downregulated (Down), Programmed Cell Death (PCD), Unfolded Protein Response (UPR), Transcriptional Regulation plus Histone Modification (Transcriptional Reg.).
Categorized Differentially Regulated Genes.
| sequence | gene name | human homolog(s) | NaAsO2 | DMA | HgCl2 | meHgCl | category | references |
|---|---|---|---|---|---|---|---|---|
| PAR2.3 | PRKAA1, PRKAA2 | – | – | – | 1.5 | AMPK, hhDG | ( | |
| ZK909.2 | PRKACA | −1.8 | −1.8 | −1.7 | – | AMPK | ( | |
| K09E9.4 | PKIA, PKIB, PKIG | – | – | −1.7 | −2.0 | AMPK | ( | |
| ZK1320.4 | CYP3A4, CYP3A43 | – | −2.1 | −1.8 | −2.0 | CYP, hhDG, mib | ( | |
| T10B9.5 | CYP3A4, CYP3A43 | −1.8 | – | – | – | CYP, hhDG, mib | ( | |
| K09A11.3 | CYP2U1 | – | −2.1 | – | – | CYP, hhDG, mib | ( | |
| K09A11.4 | CYP2U1 | – | −1.8 | – | – | CYP, hhDG, mib | ( | |
| R04D3.1 | CYP2U1 | – | 4.6 | – | – | CYP, iIR, hhDG, mib | ( | |
| T10H4.10 | CYP2U1 | – | −2.5 | – | – | CYP, DrugR hhDG, mib | ( | |
| K09D9.2 | CYP2U1 | – | −2.7 | – | – | CYP, DrugR, hhDG, mib | ( | |
| C49G7.8 | CYP2U1 | 1.6 | – | – | CYP, DrugR, hhDG, mib | ( | ||
| K07C6.2 | CYP2U1 | – | 1.9 | – | – | CYP, DrugR, hhDG, mib | ( | |
| F14H3.10 | CYP2U1 | – | 5.6 | – | – | CYP, iIR, DrugR, hhDG, mib | ( | |
| F01D5.9 | – | – | – | – | −1.5 | CYP | ( | |
| F55A8.2d | PRKG1 | – | – | −1.8 | – | DAF-2/IIS, Loco, hhDG, mib | ( | |
| ZK1251.2 | – | −1.9 | −1.9 | – | – | DAF-2/IIS, rSKN-1 | ( | |
| H42K12.1b | PDPK1 | – | 1.5 | 1.5 | – | DAF-2/IIS, hhDG, OxStrR | ( | |
| B0454.7 | – | 7.1 | 1.8 | – | – | rDAF-16 | ( | |
| F55G11.5 | – | – | −4.2 | – | – | rDAF-16 | ( | |
| F37F2.3 | GSTP1 | 6.9 | 10.4 | – | – | rDAF-16, hhDG | ( | |
| R02D3.6 | – | – | 2.3 | – | 1.6 | rDAF-16, OxStrR | ( | |
| ZK75.2 | – | −1.6 | −2.2 | −1.8 | – | rDAF-16 | ( | |
| R02D3.1 | AASS | – | – | 1.6 | – | hhDG | ( | |
| Y74C10AR.3 | ABCB7 | – | – | 1.6 | – | hhDG, OxStrR | ( | |
| T11B7.4 | LDB3, PDLIM5 | – | – | – | −2.0 | hhDG | ( | |
| Y71G12B.1 | CHAF1B | – | – | – | 1.6 | hhDG | ( | |
| E04F6.11 | CLCN2 | – | – | 1.7 | – | hhDG | ( | |
| ZC116.3 | CUBN | −2.7 | −1.7 | – | −2.5 | hhDG | ( | |
| F11H8.4 | DIAPH1, DIAPH2 | – | – | – | −2.3 | hhDG | ( | |
| ZC477.9 | VCL | – | – | 1.6 | – | hhDG | ( | |
| T12E12.4 | DNM1L | – | – | 1.6 | – | hhDG | ( | |
| F43G9.6 | DYSF | 2.5 | −1.5 | – | – | hhDG | ( | |
| ZK180.1 | GABBR2 | – | −2.1 | – | – | hhDG, DrugR | ( | |
| F45H7.2 | DLC1, | – | – | −2.1 | −2.1 | hhDG | ( | |
| F54D7.3 | GNRHR | – | – | 1.8 | – | hhDG | ( | |
| R03E9.4 | KCNJ14, KCNJ4 | – | 2.1 | – | – | hhDG | ( | |
| R13A1.2 | SLC12A4, SLC12A6 | – | – | −2.1 | – | hhDG | ( | |
| M01B2.1 | KIT, PDGFRA | – | – | – | −3.3 | hhDG | ( | |
| B0457.1 | ADGRL3 | 1.6 | – | 1.7 | – | hhDG | ( | |
| R05C11.3 | ATP2B2, ATP2B3 | – | – | 1.5 | – | hhDG | ( | |
| F32D1.10 | MCM7 | – | – | – | 1.5 | hhDG, DNArep | ( | |
| F20B6.3 | ABCC4 | – | – | – | 2.7 | hhDG | ( | |
| Y43F8C.12 | ABCC2 | 1.9 | – | 1.8 | 1.8 | hhDG | ( | |
| T22E5.5.1 | TNNT1, TNNT3 | – | – | 1.6 | – | hhDG | ( | |
| Y37A1C.1 | SLC12A2 | – | – | 1.5 | – | hhDG | ( | |
| F31B9.1 | AGTR1, GPR15 | – | – | −2.3 | – | hhDG | ( | |
| C01F6.6 | SLC9A3R1 | – | – | 1.6 | – | hhDG | ( | |
| H12C20.2 | PMS2 | – | – | – | −2.5 | hhDG, DNArep | ( | |
| K07A3.2 | PTCHD3 | – | – | – | 2.0 | hhDG | ( | |
| Y18D10A.7 | PTCHD3 | – | – | – | 2.1 | hhDG | ( | |
| F25H5.3 | PKLR, PKM | – | – | 1.9 | – | hhDG, mib | ( | |
| T08B2.5 | RBM10, RBM5 | – | – | 1.7 | – | hhDG, mib | ( | |
| F25B3.3 | RASGRP3 | – | – | −2.8 | −3.1 | hhDG | ( | |
| C06E1.10 | DHX37 | – | – | 1.8 | – | hhDG | ( | |
| T01H8.1 | RPS6KA1, RPS6KA2 | – | – | 1.5 | – | hhDG | ( | |
| C06E7.1 | MAT1A, MAT2A | – | – | 1.7 | – | hhDG, mib | ( | |
| K11G12.3 | SLC11A1, | – | – | – | −2.1 | hhDG | ( | |
| H21P03.3 | SGMS2 | – | – | 1.5 | – | hhDG | ( | |
| F55H12.1 | SLC6A11, SLC6A6 | – | – | – | 2.1 | hhDG | ( | |
| Y46G5A.30 | SLC6A8, SLC6A12 | 2.1 | – | – | – | hhDG, mib | ( | |
| Y48E1B.14 | SNX14 | – | – | 1.9 | – | hhDG | ( | |
| T19H12.11 | UGT1A9, UGT2B28 | 4.5 | – | – | – | hhDG | ( | |
| F29F11.2 | UGT1A8, UGT2B15 | 94.5 | – | – | – | hhDG | ( | |
| ZK1151.1 | DST | 1.7 | 2.0 | – | 2.9 | hhDG | ( | |
| T08G11.1 | VPS13A | – | – | 1.7 | – | hhDG | ( | |
| Y37A1A.4 | RIPOR2, RIPOR3 | −1.5 | – | – | −1.8 | hhDG | ( | |
| Y48G1C.10 | MTMR10, | – | – | – | 1.6 | hhDG | ( | |
| Y71H10B.1 | NT5C2 | – | – | 1.6 | – | hhDG, OxStrR | ( | |
| ZK1073.1 | NDRG1, NDRG2 | – | – | 1.5 | – | hhDG | ( | |
| R05F9.12 | MGAM | – | – | 1.6 | – | iIR, hhDG | ( | |
| K02G10.7 | AQP9 | – | 2.2 | – | – | iIR | ( | |
| ZK896.7 | – | – | – | – | −1.9 | iIR, rMAPK | ( | |
| C41H7.7 | – | 9.9 | 5.8 | – | – | iIR | ( | |
| Y46C8AL.3 | – | – | −8.6 | −5.6 | iIR | ( | ||
| F58E6.7 | – | −1.9 | −2.3 | −1.9 | −2.0 | iIR | ( | |
| F26A1.10 | 1.5 | 2.1 | – | – | iIR | ( | ||
| C05A9.1 | ABCB1 | – | −2.3 | – | – | iIR, DrugR | ( | |
| C05C10.4 | – | 1.6 | 2.2 | – | – | iIR, rDAF-16 | ( | |
| C43H6.6 | – | – | – | – | 1.7 | iIR | ( | |
| F01D5.2 | – | 4.9 | 3.1 | – | – | iIR | ( | |
| F26D2.3 | GCNT1, GCNT3 | – | – | – | 2.0 | iIR, hhDG | ( | |
| F47B3.7 | – | – | 2.6 | – | – | iIR | ( | |
| F48E3.9 | – | 2.2 | – | – | – | iIR | ( | |
| H12I13.5 | – | 1.8 | – | – | 1.7 | iIR | ( | |
| K02D3.1 | – | −3.3 | – | – | – | iIR | ( | |
| R04B5.11 | – | – | 2.6 | – | – | iIR | ( | |
| R09H10.5.2 | – | – | – | 2.1 | – | iIR | ( | |
| T01B6.1 | SAPCD2 | 2.1 | – | – | – | iIR | ( | |
| T28A11.2 | – | – | 3.6 | – | – | iIR | ( | |
| B0207.12 | GLRA3, GLRA4 | 2.0 | 2.6 | 1.6 | – | Loco, DrugR | ( | |
| K04F10.4 | PCSK5, PCSK6 | −1.5 | – | – | – | Loco, hhDG | ( | |
| F46C8.5 | LHX-3, LHX4 | – | – | −1.7 | – | Loco, TxR, hhDG, mib | ( | |
| C55B7.12 | ZNF500 | – | −2.6 | – | – | Loco, TxR, mib | ( | |
| Y41C4A.4 | ATF1, CREB1, CREM | – | – | −2.5 | – | Loco, TxR, hhDG | ( | |
| F15A8.5 | DRD1, DRD5 | – | 1.6 | – | – | Loco, hhDG | ( | |
| C16C2.2 | RGS9, RGS11 | – | – | −1.6 | – | Loco, hhDG | ( | |
| C06A12.4 | GUCY2D | – | – | −2.2 | – | Loco, hhDG | ( | |
| T15H9.3 | ASCL3 | – | −1.8 | – | – | Loco, TxR | ( | |
| F58A3.1 | LDB1, LDB2 | – | – | 1.6 | – | Loco, TxR, rDAF-16 | ( | |
| T07H8.4 | – | −1.5 | −1.7 | 1.5 | – | Loco | ( | |
| E01F3.1 | PDE3A | −1.6 | – | – | – | Loco, TxR, hhDG | ( | |
| Y11D7A.4 | RAB28 | – | −2.4 | – | – | Loco, hhDG | ( | |
| M01G5.5 | SLC6A5, SLC6A14 | – | – | 1.6 | – | Loco, hhDG | ( | |
| C18A3.5 | TIA1, TIAL1 | – | – | 1.9 | – | Loco, OxStrR | ( | |
| F56A12.1 | SIX4, SIX6 | – | −1.9 | – | – | Loco, TxR, hhDG | ( | |
| ZC101.2 | HSPG2 | −1.6 | – | – | – | Loco, hhDG | ( | |
| C11D2.6 | NALCN | – | – | – | −2.0 | Loco | ( | |
| C09D1.1 | SPEG | – | – | −1.6 | – | Loco, hhDG | ( | |
| F35C8.3 | MAP2K7 | – | – | 1.9 | – | MAPK, Loco, mib | ( | |
| K02H8.1 | MBNL1, MBNL2 | −2.0 | 1.9 | – | – | MAPK, T | ( | |
| ZC504.4 | MINK1, TNIK | – | – | −1.9 | −2.1 | MAPK, hhDG | ( | |
| Y95B8A.10 | PDE8A, PDE8B | – | – | – | −2.2 | MAPK, hhDG, mib | ( | |
| K11E8.1 | CAMK2D | – | – | −2.0 | – | MAPK, TxR, hhDG, mib | ( | |
| W02G9.2.3 | KLHL8 | – | – | – | 1.6 | rMAPK | ( | |
| F21F8.4 | CTSE, PGA4, PGC | – | −1.9 | – | −1.5 | PCD | ( | |
| Y39B6A.23 | CTSE, PGA4, PGC | – | −2.3 | – | – | PCD | ( | |
| Y47H9C.4 | MEGF10, MEGF11 | – | – | 1.5 | – | PCD, UPR, iIR, hhDG | ( | |
| F08F1.5 | XKR4, XKR6, XKR7 | – | −1.5 | – | – | PCD | ( | |
| C09G12.8 | RAC1, RAC2 | – | – | −1.6 | – | PCD, hhDG | ( | |
| F43G9.11 | SCRT1, SCRT2 | – | −3.4 | – | – | PCD, TxR | ( | |
| ZK909.4 | DBP,TEF | – | −3.4 | – | – | PCD, TxR, hhDG | ( | |
| T21H3.3 | CALM1 | – | – | −1.5 | – | PCD, hhDG, mib | ( | |
| T12E12.4 | DNM1L | – | – | 1.6 | – | PCD, hhDG | ( | |
| C02C6.1 | DNM1, DNM2 | – | – | 1.5 | – | PCD, Loco, hhDG | ( | |
| C49A1.4 | EYA1, EYA2, EYA4 | – | −1.7 | – | – | PCD, TxR, OxStrR, Loco, UPR, DNArep, hhDG, mib | ( | |
| M05B5.5 | TCF3, TCF4, TCF12 | −1.7 | – | – | – | PCD, TxR, hhDG | ( | |
| Y37A1B.2 | SNX18, SNX33 | – | – | 1.9 | – | PCD | ( | |
| Y51H1A.6 | – | – | – | 1.6 | – | PCD, mib | ( | |
| C33A11.1 | NFKBIZ | – | – | 1.5 | – | PCD, TxR | ( | |
| ZK524.1 | – | – | −1.7 | – | – | PCD, Notch | ( | |
| F11F1.7 | – | – | −2.4 | −2.0 | −1.8 | PCD | ( | |
| T19E7.2 | NFE2L1, | – | – | – | 1.5 | SKN-1, TxR, OxStrR, UPR, iIR, rMAPK, hhDG | ( | |
| K10C2.3 | CTSE, PGA3 | 2.3 | 2.3 | – | – | rSKN-1, iIR, rAMPK, rMAPK | ( | |
| C12C8.2 | – | 2.1 | – | – | – | rSKN-1, iIR | ( | |
| F35E8.11 | FAXC | – | 5.0 | – | – | rSKN-1, iIR, rDAF-16, | ( | |
| ZK666.6 | – | −2.2 | −2.2 | – | – | rSKN-1, iIR | ( | |
| ZK673.9 | – | 2.8 | – | – | – | rSKN-1, iIR | ( | |
| K10B2.2 | CTSA | 1.9 | – | – | – | rSKN-1, iIR | ( | |
| F02C12.5 | CYP3A4, CYP3A5 | – | −3.0 | – | – | rSKN-1, CYP, hhDG, mib | ( | |
| K10H10.3 | WWOX | 1.8 | 4.3 | – | – | rSKN-1, hhDG | ( | |
| K10D11.1 | – | 6.4 | 2.6 | – | – | rSKN-1, iIR | ( | |
| C32H11.12 | – | 5.3 | 1.7 | – | – | rSKN-1, iIR | ( | |
| Y4C6B.6 | GBA | – | – | – | −4.7 | rSKN-1, iIR, hhDG | ( | |
| F37B12.2 | GCLC | 1.8 | 1.6 | – | – | rSKN-1, OxStrR | ( | |
| R107.7 | GSTP1 | 1.6 | 1.7 | – | – | rSKN-1, UPR, hhDG | ( | |
| R03D7.6 | HPGDS | – | 3.0 | – | – | rSKN-1, iIR | ( | |
| F11G11.3 | HPGDS | – | 1.8 | – | – | rSKN-1 | ( | |
| F11G11.2 | HPGDS | – | 1.5 | – | – | rSKN-1 | ( | |
| F11G11.1 | HPGDS | – | 1.6 | – | – | rSKN-1 | ( | |
| Y45G12C.2 | GSTP1 | 2.1 | 2.1 | – | – | rSKN-1, OxStrR, hhDG | ( | |
| F37B1.2 | HPGDS | 3.8 | 5.9 | – | – | rSKN-1, OxStrR | ( | |
| T26C5.1 | HPGDS | 1.6 | 2.0 | – | – | rSKN-1, iIR | ( | |
| F37B1.3 | HPGDS | 2.8 | 4.0 | – | – | rSKN-1, iIR, OxStrR | ( | |
| F37B1.5 | HPGDS | 5.8 | 6.8 | – | – | rSKN-1 | ( | |
| F37B1.8 | HPGDS | −2.2 | −2.2 | – | −3.2 | rSKN-1 | ( | |
| ZK546.11 | HPGDS | 5.3 | 7.5 | – | – | rSKN-1 | ( | |
| Y1H11.2 | HPGDS | 2.1 | 6.4 | – | – | rSKN-1 | ( | |
| C02D5.3 | GSTO1, GSTO2 | 4.1 | 5.3 | – | – | rSKN-1, OxStrR | ( | |
| ZK84.3 | – | 1.8 | 2.3 | −1.8 | 2.3 | rSKN-1, rMAPK, rDAF-16 | ( | |
| F35E12.5 | – | 1.9 | 2.7 | – | – | rSKN-1, iIR, rMAPK | ( | |
| T22G5.6 | FABP5, PMP2 | – | 7.2 | – | – | rSKN-1, hhDG | ( | |
| K08H10.2 | PLIN4 | – | – | 1.5 | – | rSKN-1, rUPR | ( | |
| ZK1058.6 | – | 3.6 | 2.2 | – | – | rSKN-1, rMAPK | ( | |
| H12D21.1 | – | 10.7 | 8.7 | – | – | rDAF-16 | ( | |
| ZC412.6 | – | 9.4 | 7.5 | – | – | rSKN-1, iIR | ( | |
| W06A7.5 | – | 34.0 | 21.8 | – | – | rSKN-1 | ( | |
| F57C9.1 | PDXK | 2.0 | 2.0 | – | – | rSKN-1, mib | ( | |
| C55A6.5 | CBR3 | – | 2.2 | – | – | rSKN-1 | ( | |
| C15F1.7 | SOD1 | – | 1.7 | – | – | rSKN-1, OxStrR, mib | ( | |
| H23N18.1 | UGT1A1, UGT2B28, UGT2B7 | 2.3 | – | – | – | rSKN-1, iIR, hhDG | ( | |
| B0348.2 | – | −1.5 | −1.9 | – | – | rSKN-1, mib | ( | |
| C17H12.6 | – | 2.2 | – | – | – | rSKN-1, iIR | ( | |
| C32H11.3 | – | 10.1 | 6.6 | – | – | rSKN-1, iIR | ( | |
| C32H11.4 | – | 11.7 | 6.7 | – | – | rSKN-1, iIR | ( | |
| F01D5.3 | – | 3.4 | 3.3 | – | – | rSKN-1, iIR | ( | |
| F01D5.5 | – | 2.9 | – | – | – | rSKN-1, iIR | ( | |
| F39B2.3 | CRYZ | 1.9 | 2.0 | – | – | rSKN-1, T | ( | |
| F55G11.2 | – | 10.4 | 2.9 | – | – | rSKN-1, iIR | ( | |
| F56D5.3 | – | 3.1 | 1.8 | – | – | rSKN-1, OxStrR | ( | |
| H25K10.1 | ACP7 | 1.9 | – | – | – | rSKN-1, iIR, mib | ( | |
| W06H8.2 | – | 4.9 | 4.4 | – | – | rSKN-1 | ( | |
| Y73B6BL.14 | – | 2.1 | 2.0 | – | – | rSKN-1, DNArep | ( | |
| ZK742.4 | – | 2.3 | 2.8 | – | – | rSKN-1, rDAF-16 | ( | |
| R186.8 | – | −1.8 | – | – | – | T | ( | |
| Y80D3A.2 | AQR | 1.9 | – | – | – | T | ( | |
| Y48G10A.4 | INTS8 | – | – | 1.5 | 1.5 | T | ( | |
| D1007.12 | RPL24 | 1.9 | – | – | – | T | ( | |
| Y92C3B.2 | U2AF2 | – | – | – | 1.6 | TlR | ( | |
| Y53C12B.3 | – | – | −2.1 | 2.1 | 2.3 | T | ( | |
| F29C12.3 | RICTOR | – | – | 1.8 | – | TOR | ( | |
| F56A3.5 | CBFB | – | −2.0 | – | −2.8 | TxR | ( | |
| H25P06.2 | CDK9 | – | – | 1.7 | – | TxR, hhDG | ( | |
| C16C2.1 | NOTO, VAX1 | – | −2.8 | – | −1.8 | TxR, hhDG | ( | |
| ZK265.4 | RAX | – | −3.1 | – | – | TxR, hhDG | ( | |
| C13G5.1 | EN1, EN2 | – | – | −1.8 | – | TxR, hhDG | ( | |
| C37E2.4 | OTX1, OTX2 | – | −2.1 | – | – | TxR, hhDG | ( | |
| ZK993.1 | GSC | – | – | −2.2 | – | TxR | ( | |
| F34D6.2 | ZHX1 | −1.9 | – | – | – | TxR | ( | |
| T23D8.8 | ARID3A, ARID3C | 1.7 | 2.1 | – | – | TxR | ( | |
| F44B9.3 | CCNT1 | – | – | 1.8 | – | TxR | ( | |
| C15C8.2 | NPAS4 | – | −2.1 | – | – | TxR | ( | |
| C34E10.7 | NEUROD1 | – | −2.4 | – | – | TxR, hhDG | ( | |
| F25E2.5 | SMAD4 | – | −1.6 | −2.4 | −2.3 | TxR, TGFβ, hhDG, mib | ( | |
| C27C12.6 | DMRT3 | – | −1.8 | – | – | TxR | ( | |
| F54F7.7 | DOT1L | 1.6 | – | – | – | TxR, DNArep | ( | |
| F49E12.6 | E2F7 | – | −1.9 | – | – | TxR | ( | |
| C08C3.1 | HOXB8 | – | – | −1.7 | – | TxR | ( | |
| F40H3.4 | FOXR1 | – | −2.7 | – | −1.6 | TxR | ( | |
| C14B9.6 | NCOR1 | 1.7 | – | – | – | TxR | ( | |
| ZK131.3 | – | – | – | – | −1.7 | TxR | ( | |
| ZK131.5 | H2BC1 | – | 1.7 | – | −1.6 | TxR | ( | |
| F38C2.2 | BHLHE23 | −1.7 | −1.7 | – | – | TxR | ( | |
| T01D3.2 | NPAS1 | – | −3.7 | – | −2.1 | TxR, hhDG | ( | |
| F43G6.6 | KDM7A | – | – | −2.1 | – | TxR, hhDG, mib | ( | |
| F23D12.5 | KDM6A, UTY | – | −1.7 | – | – | TxR, hhDG | ( | |
| F20H11.2 | SBNO1 | – | – | – | 1.5 | TxR | ( | |
| T14F9.5 | ATOH1 | – | −1.8 | – | – | TxR, hhDG | ( | |
| C01H6.5 | RORC | 1.8 | – | – | – | TxR, hhDG | ( | |
| C25E10.1 | – | – | – | −2.5 | – | TxR, mib | ( | |
| F44C4.2 | PPARA | – | – | – | −2.2 | TxR, hhDG, mib | ( | |
| T09A12.4 | – | – | – | 1.5 | – | TxR, mib | ( | |
| H12C20.3 | – | – | – | – | −1.7 | TxR, mib | ( | |
| C47F8.8 | – | 1.9 | – | – | – | TxR, mib | ( | |
| T13F3.3 | PPARA | – | −4.0 | – | −2.0 | TxR, mib | ( | |
| C03G6.8 | HNF4A, HNF4G | – | −3.1 | −2.0 | −2.1 | TxR, hhDG, mib | ( | |
| C06B8.1 | PPARA | – | −2.4 | −1.8 | −1.6 | TxR, hhDG, mib | ( | |
| C54F6.8 | – | – | −2.4 | −1.9 | −1.8 | TxR, mib | ( | |
| F47C10.4 | – | – | −2.3 | −1.7 | – | TxR, mib | ( | |
| F47C10.7 | – | – | −1.7 | −1.7 | TxR, mib | ( | ||
| R07B7.14 | HNF4A, HNF4G | – | – | – | −1.6 | TxR, hhDG, mib | ( | |
| T07C5.3 | – | – | −4.4 | – | – | TxR | ( | |
| T13F3.2 | PPARA | – | −3.8 | – | – | TxR, mib | ( | |
| Y116A8C.18 | – | – | – | – | −2.6 | TxR, mib | ( | |
| F21D12.5 | – | – | −1.7 | −1.8 | −1.8 | TxR | ( | |
| M6.3 | HHEX | −1.6 | −1.9 | – | −1.8 | TxR | ( | |
| F38A6.1 | FOXA1, FOXA2 | −1.5 | – | – | – | TxR | ( | |
| C47C12.3 | ZIC1 | – | −2.0 | −1.7 | – | TxR, hhDG | ( | |
| F26A3.8 | – | – | – | 1.8 | – | TxR | ( | |
| T05A10.1 | HIVEP1 | – | – | −1.6 | – | TxR, TGFβ, hhDG | ( | |
| Y43F4B.3 | – | – | – | 1.8 | – | TxR, mib | ( | |
| W02H5.7 | NFE2L1 | – | – | −1.5 | – | TxR, hhDG | ( | |
| T08A11.2 | SF3B1 | – | – | 1.7 | – | TxR, hhDG | ( | |
| F31E8.3 | BSX | −1.6 | −2.6 | −2.0 | −1.7 | TxR | ( | |
| T07C4.2 | EOMES, | – | – | −2.3 | – | TxR, hhDG | ( | |
| D2030.9 | DCAF11 | 1.5 | 1.5 | – | – | TxR | ( | |
| ZC123.3 | ZFHX3 | – | – | 1.5 | – | Txr, hhDG | ( | |
| Y48G8AL.10 | ZNF729, ZNF99 | – | – | – | 1.9 | TxR, hhDG | ( | |
| D1044.6 | ZNF318 | 2.1 | – | – | – | TxR | ( | |
| F26A10.2 | ZNF148 | – | – | −2.3 | – | TxR | ( | |
| M03D4.4 | ZNF653 | – | −3.3 | – | – | TxR | ( | |
| R10E4.11 | – | – | – | −1.6 | – | TxR | ( | |
| Y111B2A.10 | ZNF689 | – | −1.7 | −2.4 | −2.6 | TxR | ( | |
| Y53C10A.15 | – | – | – | – | −2.2 | TxR | ( | |
| Y56A3A.28 | – | – | – | −2.4 | – | TxR | ( | |
| Y57G11C.9 | PPHLN1 | – | – | −2.0 | – | TxR | ( | |
| C03A7.14 | – | – | −2.5 | – | – | UPR | ( | |
| T10B5.5 | CCT7 | – | – | 1.9 | – | UPR, Loco | ( | |
| ZK970.2 | CLPP | −1.8 | – | – | – | UPR, hhDG | ( | |
| F38A5.13 | DNAJC2 | – | – | −2.0 | – | UPR | ( | |
| F39B2.10 | DNAJA1, DNAJA4 | – | – | 1.6 | – | UPR, mib | ( | |
| ZK1193.5 | SATB2 | – | – | −1.7 | −1.6 | UPR, TxR, hhdG | ( | |
| T12D8.8 | ST13 | – | −1.6 | – | – | UPR | ( | |
| T22A3.2 | HSPB2 | – | −2.0 | – | – | UPR | ( | |
| Y46H3A.2 | CRYAB, HSPB6 | – | – | −1.6 | – | UPR, iIR, hhDG | ( | |
| T27E4.3 | – | −1.5 | – | – | – | UPR | ( | |
| C15H9.6.3 | HSPA5 | – | – | 1.7 | – | UPR | ( | |
| ZK256.1 | ATP2C1 | – | – | 1.5 | – | UPR, iIR, OxStrR, hhDG | ( | |
| T02C5.5 | CACNA1A | −1.5 | – | – | – | UPR, TGFβ, hhDG, Loco, mib | ( | |
| W01B6.1 | WNT5A | – | −1.7 | −1.6 | – | Wnt, hhDG | ( | |
| F58G4.4 | – | −3.4 | −2.6 | −2.3 | −2.7 | rWnt | ( |
AMPK, effector of AMP-activated Protein Kinase Signaling; rAMPK, regulated by effectors of AMPK signaling; DAF-2/IIS, effector of the Insulin/Insulin-like Growth Factor Signaling Pathway; rDAF-16, regulated by DAF-16 in the same direction; DNArep, DNA replication/repair; DrugR, response to drug, xenobiotic metabolic process; hhDG, close homology to human disease gene(s); iIR, innate Immune Response (≥1.5x change in the same direction with exposure to ≥ two different pathogens or in ≥ two studies, or role in iIR described); Loco, involved in locomotion or behavior; MAPK, effector of Mitogen-Activated Protein Kinase Signaling (ERK, p38, JUK/SAPK); rMAPK, regulated by effectors of MAPK signaling; mib, metal ion binding; OxStrR, oxidative stress response; PCD, effector of programmed cell death and/or apoptotic process; rSKN-1, regulated by Nrf/SKN-1 in the same direction; TGFβ, effector of transforming growth factor beta receptor signaling pathway; TlR, Translational regulation and machinery; TOR, effector of TOR signaling; TxR, transcriptional regulation and/or histone modification; UPR, effector of unfolded protein/heat shock response; rUPR, regulated by UPR effectors; Wnt, effector of Wnt signaling; rWnt, regulated by Wnt signaling.
Fig. 4Curation of DEGs with the greatest fold-change. (A-B) A subset of the most highly differentially regulated genes were further researched for functional information. Abbreviations: regulated (Reg.) in the same direction by DAF-16 or Nrf/SKN-1, genes that respond in the same direction to pathogen exposure (Immune Resp.).
Fig. 5Assessment of Oxidative Stress Response (OxStrR) Biomarkers. (A-B) Examples of bright field and fluorescence images of C. elegans carrying an integrated transgene with the promoter for phase II enzyme gst-4 fused to GFP to monitor OxStrR. (C-F) Biosensor fold-change relative to water control, from at least three independent experiments per exposure group. Top concentrations shown are maximum concentration not altering adult size and optical density below 80% of control. Error bars: standard error of the mean (SEM), T-test p-values *<0.05, ** <0.005.
Fig. 6Assessment of Unfolded Protein Response (UPR) Biomarkers. (A-D) UPR response biosensor fold change relative to water control, from at least three independent experiments per exposure group. (A&C) Proteasome specific UPR reporter aip-1p::GFP. (B&D) Endoplasmic reticulum specific UPR reporter hsp-4p::GFP (+ve control: 30 µg/ml Tunicamycin). Top concentrations shown are the maximum concentration not altering adult size or optical density below 80% of control. Error bars: standard error of the mean (SEM), T-test p-values *<0.05, ** <0.005.